⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL220828 | 0.87 | CYP19A1 (0.34) | — | |
| SCHEMBL7074142 | 0.76 | — | — | |
| SCHEMBL4769982 | 0.71 | CYP19A1 (0.33) | — | |
| SCHEMBL14463804 | 0.68 | PDE3B (0.38) | — | |
| SCHEMBL4986873 | 0.67 | DRD2 (0.38) | — | |
| SCHEMBL22579802 | 0.65 | TDP1 (0.42) | — | |
| SCHEMBL790074 | 0.65 | DRD2 (0.37) | — | |
| SCHEMBL14863188 | 0.65 | — | — | |
| SCHEMBL516862 | 0.65 | NISCH (0.36) | — | |
| SCHEMBL2439123 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2444401-B1 | NOVEL IMIDAZOPYRIDINE COMPOUND | ONO PHARMACEUTICAL CO (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-8569504-B2 | Imidazopyridine compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| EP-2444401-A1 | NOVEL IMIDAZOPYRIDINE COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2012-04-25 | — | — | EP | disclosed |
| US-20120094944-A1 | NOVEL IMIDAZOPYRIDINE COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-1420796-A4 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | MERCK & CO INC (US) | 2007-07-11 | — | — | EP | disclosed |
| EP-1420796-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | Merck & Co., Inc. (US) | 2004-05-26 | — | — | EP | disclosed |
| US-6645974-B2 | Administering an androstamide compound; osteoporosis, anticancer agents, glandular disorders | MERCK & CO., INC. | 2003-11-11 | — | — | US | disclosed |
| US-20030065004-A1 | Androgen receptor modulators and methods for use thereof | MERCK SHARP & DOHME CORP. | 2003-04-03 | — | — | US | disclosed |
| WO-2003011302-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | MERCK & CO., INC. (US) | 2003-02-13 | — | — | WO | disclosed |
| EP-0676398-B1 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO CO (JP) | 2001-10-24 | — | — | EP | disclosed |
| US-6117893-A | Heterocyclic compounds having anti-diabetic activity and their use | SANKYO COMPANY, LIMITED (JP) | 2000-09-12 | — | — | US | disclosed |
| EP-1022274-A1 | Oxazolidinedione and Thiazolidinedione derivatves, their preparation and their use | Sankyo Company Limited (JP) | 2000-07-26 | — | — | EP | disclosed |
| US-5977365-A | HYPOGLYCEMIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1999-11-02 | — | — | US | disclosed |
| US-5962470-A | Heterocyclic compounds having anti-diabetic activity and their use | SANKYO COMPANY, LIMITED (JP) | 1999-10-05 | — | — | US | disclosed |
| US-5834501-A | TREATING DIABETES OR HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 1998-11-10 | — | — | US | disclosed |
| US-5739345-A | HYPOGLYCEMIC AND ANTIDIABETIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1998-04-14 | — | — | US | disclosed |
| US-5624935-A | ANTIDIABETIC AGENTS, HYPOGLYCEMIC AGENTS OR ANTILIPEMIC AGENTS | SANKYO COMPANY, LIMITED | 1997-04-29 | — | — | US | disclosed |
| EP-0676398-A2 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1995-10-11 | — | — | EP | disclosed |